Clinical trial
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in…
NCT00172081 · Shire, Industry · Completed
Key facts
| NCT number | NCT00172081 |
|---|---|
| Title | TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis |
| Official title | An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | placebo, ALX1-11 |
| Enrollment | 2,532 |
| Start date | Apr 27, 2000 |
| Primary completion | Nov 7, 2003 |
| Completion | Nov 7, 2003 |
| First posted | Sep 15, 2005 |
| Last update posted | May 14, 2021 |
| Countries | Argentina, Brazil, Bulgaria, Canada, Israel, Mexico, Romania, Russia, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: